
CLAIMS

1. A pharmaceutical composition for modulating wound healing processes or treating pulmonary fibrosis in a subject, comprising a phosphonate prodrug of a phosphonotetrahydropyran compound of a compound of Formula I:




Formula I

and an acceptable pharmaceutical carrier


wherein the phosphonate prodrug is a mono- or di-ester of the phosphonic acid functionality; and

wherein n is an integer from 0 to 3, the $-O(CH_2)_nR$ group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of –Cl, –F, CF_3, CH_3, CH_2CH_3, $-OCH_3$, $-OCF_3$, $-(CH_2)_mCO_2R^1$, $-(CH_2)_mOR^2$, $-(CH_2)_mCONHR^2$, $-(CH_2)_mNHR^2$, and $-(CH_2)_mCONR^2R^3$, wherein m is an integer from 0 to 3; R^1 is selected from the group of consisting of H, alkyl and aryl; and R^2 and R^3 are independently selected from the group consisting of H, alkyl, aryl and acyl.

2. The pharmaceutical composition of claim 1 wherein the phosphonate prodrug is selected from the group consisting of:




and




wherein X is a hydrogen or substituted alkyl and Px is alkyl.

3. The pharmaceutical composition of claim 2 wherein phosphonate prodrug is selected from the group consisting of:




and



4. The pharmaceutical composition of claim 1, wherein the composition is for treating pulmonary fibrosis and further comprises a compound selected from the group consisting of N-acetyl cysteine, aminoguanidine, anti-VEGF antibody, Batimastat, Bosentan, dexamethasone, difluoromethylornithine, Etanercept, Gefitinib, Imatinib, methylprednisolone, Pentoxifylline, Pirfenidone, prednisolone, Rosiglitazone, TGF-beta antibody, TNF-alpha antibody, and Vinblastine.

WE CLAIM:

1. A method to modulate the inflammation and wound healing processes in a subject, said method comprising the administration of a composition containing an effective amount of a phosphotetrahydropyran compound, the salt of a phosphotetrahydropyran compound or a phosphonate prodrug of a phosphonotetrahydropyran compound, and an acceptable pharmaceutical carrier, wherein the phosphotetrahydropyran compound has the formula I:



Formula I

wherein n is an integer from 0 to 3, the $-O(CH_2)_nR$ group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of –Cl, -F, CF_3, CH_3, CH_2CH_3, $–OCH_3$, $–OCF_3$, $-(CH_2)_mCO_2R^1$, $-(CH_2)_mOR^2$, $-(CH_2)_mCONHR^2$, $-(CH_2)_mNHR^2$, and $-(CH_2)_mCONR^2R^3$, wherein m is an integer from 0 to 3; R^1 is selected from the group of consisting of H, alkyl and aryl; and R^2 and R^3 are independently selected from the group consisting of H, alkyl, aryl and acyl.

2. The method of Claim 1 where the subject has a disease or disorder associated with the deposition of excess collagen, fibronectin and or other extracellular matrix components.

3. The method of Claim 2 where the disease or disorder is lung fibrosis, glaucoma, scleroderma, liver fibrosis, cardiac fibrosis, renal fibrosis or renal failure.

4. The method of Claim 1 where wound healing process is subsequent to a surgical procedure.

5. The method of Claim 4 where the surgical procedure involves eye surgery.

6. The method of Claim 4 where the surgical procedure is performed on internal organs and tissues.

7. The method of Claim 4 where the surgical procedure is performed on the epidermal layer.

8. The method of Claim 7 where the surgical procedure may lead to keloid formation.

9. The method of Claim 7 where the surgical procedure is associated with cosmetic or plastic surgery.

10. The method of claim 4 where the surgical procedure is to repair tendon injury.


11. The method of Claim 1 where the composition is administered to the site of inflammation and wound healing.

12. The method of Claim 11 where the composition is administered directly to the lung.

13. The method of Claim 11 where the composition is administered directly to the eye.

14. The method of Claim 11 where the composition is administered directly to the wound after a surgical procedure.

15. The method of treating pulmonary fibrosis, comprising administering to a subject in need of treatment, an effective amount of a composition comprising a compound of Formula I, the sodium salt of a compound of Formula I, the phosphonate prodrug of a compound of Formula I:




Formula I

wherein n is an integer from 0 to 3, the $-O(CH_2)_nR$ group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of –Cl, -F, CF_3, CH_3, CH_2CH_3, $–OCH_3$, $–OCF_3$, $-(CH_2)_mCO_2R^1$, $-(CH_2)_mOR^2$, $-(CH_2)_mCONHR^2$, $-(CH_2)_mNHR^2$, and $-(CH_2)_mCONR^2R^3$, wherein m is an integer from 0 to 3; R^1 is selected from the group of consisting of H, alkyl

and aryl; and R^2 and R^3 are independently selected from the group consisting of H, alkyl, aryl and acyl.

16. The method of claim 15, wherein the subject suffers from idiopathic pulmonary fibrosis or other fibrotic disorders of the lung.


17. A method of treating pulmonary fibrosis, comprising co-administering to a subject in need of treatment, an effective amount of a composition comprising a compound of Formula I, the sodium salt of a compound of Formula I, the phosphonate prodrug of a compound of Formula I and one compound selected from N-acetyl cysteine, aminoguanidine, anti-VEGF antibody, Batimastat, Bosentan, dexamethasone, difluoromethylornithine, Etanercept, Gefitinib, Imatinib, methylprednisolone, Pentoxifylline, Pirfenidone, prednisolone, Rosiglitazone, TGF-beta antibody, TNF-alpha antibody, and Vinblastine:



Formula I

wherein n is an integer from 0 to 3, the $-O(CH_2)_nR$ group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of –Cl, -F, CF_3, CH_3, CH_2CH_3, $–OCH_3$, $–OCF_3$, $-(CH_2)_mCO_2R^1$, $-(CH_2)_mOR^2$, $-(CH_2)_mCONHR^2$, $-(CH_2)_mNHR^2$, and $-(CH_2)_mCONR^2R^3$, wherein m is an integer from 0 to 3; R^1 is selected from the group of consisting of H, alkyl and aryl; and R^2 and R^3 are independently selected from the group consisting of H, alkyl, aryl and acyl.


18. The method of one of claims 1-17 wherein the compound of Formula I is selected from the group consisting of:



19. The method of one of claims 1-17 wherein the subject is a human.

20. The method of claim 18 wherein the subject is a human.

21. Use of a compound of formula:



Formula I

wherein n is an integer from 0 to 3, the $-O(CH_2)_nR$ group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of –Cl, -F, CF_3, CH_3, CH_2CH_3, $–OCH_3$, $–OCF_3$, $-(CH_2)_mCO_2R^1$, $-(CH_2)_mOR^2$, $-(CH_2)_mCONHR^2$, $-(CH_2)_mNHR^2$, and $-(CH_2)_mCONR^2R^3$, wherein m is an integer from 0 to 3; R^1 is selected from the group of consisting of H, alkyl and aryl; and R^2 and R^3 are independently selected from the group consisting of

H, alkyl, aryl and acyl in the manufacture of a medicament for the treatment of pulmonary fibrosis.